Biocon Share Price Target 2024, 2025, 2030, 2050
Biocon Limited, established in 1978, is a renowned Indian biopharmaceutical business that has advanced globally. One of India’s leading biotechnology companies, Biocon develops and manufactures biosimilars, innovative biologics, and complicated small molecule APIs.
Innovation and affordability in healthcare have made the firm a biopharmaceutical leader.
What is Biocon Industries Ltd NSE: BIOCON?
Contents
- 1 What is Biocon Industries Ltd NSE: BIOCON?
- 2 Biocon Share Price Target Tomorrow
- 3 Biocon Share Price Target 2024
- 4 Biocon Share Price Target 2025
- 5 Share Price Target 2030
- 6 Share Price Target 2050
- 7 Should I buy Biocon stock?
- 8 Biocon Industries Ltd Earning Results
- 9 Expert Forecasts on the Future of Biocon Industries Ltd.
- 10 Is Biocon stock good to buy? (Bull case & Bear case)
- 11 Conclusion
- 12 FAQs
Bangalore-based Biocon Industries Ltd (NSE: BIOCON) is a significant biopharmaceutical firm. The business does cutting-edge diabetes, cancer, and immunology research. Biocon’s business approach includes biosimilar, new biologic, and branded formulation development. Biocon is a biotechnology powerhouse with a worldwide presence and strategic agreements with major pharmaceutical corporations.
Fundamental Table
| Metric | Value |
| Market Cap | ₹437.60B |
| P/E Ratio | 27.68 |
| Dividend Yield | 0.14% |
| 52-Week High | ₹395.80 |
| 52-Week Low | ₹217.50 |
Key Metrics Table
| Metric | Value |
| Revenue (TTM) | ₹34.33B |
| Net Income (TTM) | ₹6.60B |
| EPS (TTM) | ₹5.31 |
| EBITDA | ₹5.96B |
| Debt to Equity | Not available |
Peers & Comparison Table
| Company | Market Cap (₹B) | P/E Ratio |
| Biocon | 437.60 | 27.68 |
| Dr. Reddy’s | 873.49 | 28.75 |
| Sun Pharma | 2,549.26 | 36.81 |
| Cipla | 938.99 | 33.24 |
| Lupin | 466.91 | 42.17 |
| Price Type | Minimum | Maximum |
| Tomororw | -7.95 | +7.80 |
Biocon is a prominent biopharmaceutical brand that researches, develops, and manufactures biosimilars and new biologics. It creates and tests its items internally. Its diverse product line strengthens its market position. Biocon employs nearly 16,000 people using cutting-edge technologies. It aspires to develop inexpensive, high-quality biopharmaceuticals on schedule. For 2024, the price goal is ₹450. Our study predicts a price range of ₹250 to ₹450.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2024 | 250 | 450 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 250 | 300 |
| February | 250 | 300 |
| March | 240 | 290 |
| April | 250 | 320 |
| May | 280 | 330 |
| June | 270 | 360 |
| July | 320 | 390 |
| August | 320 | 390 |
| September | 340 | 420 |
| October | 320 | 430 |
| November | 330 | 450 |
| December | 300 | 450 |
Biocon strengthens its biopharmaceutical market position. Expanding their biosimilar portfolio and entering new areas could boost revenue. Strategic collaborations and R&D expenditures should benefit the organization. Their production capabilities are developing to satisfy demand. For 2025, the price objective is ₹530. Our study predicts a price range of ₹300 to ₹530.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2025 | 300 | 530 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 300 | 460 |
| February | 320 | 470 |
| March | 330 | 480 |
| April | 350 | 485 |
| May | 320 | 490 |
| June | 310 | 495 |
| July | 340 | 500 |
| August | 370 | 505 |
| September | 400 | 510 |
| October | 450 | 515 |
| November | 380 | 520 |
| December | 450 | 530 |
Biocon wants to lead biopharmaceutical innovation worldwide by 2030. With a varied portfolio of biosimilars and new biologics, the business should be robust in key global markets. Their advanced research and development may lead to breakthrough medicines. Biocon’s sustainability and cheap healthcare solutions should appeal globally. For 2030, the price objective is ₹1000. Our study predicts a price range of ₹800 to ₹1000.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2030 | 800 | 1000 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 800 | 820 |
| February | 820 | 840 |
| March | 840 | 860 |
| April | 860 | 880 |
| May | 880 | 900 |
| June | 900 | 920 |
| July | 920 | 940 |
| August | 940 | 960 |
| September | 960 | 970 |
| October | 970 | 980 |
| November | 980 | 990 |
| December | 990 | 1000 |
Biocon is expected to dominate biotechnology and customized medicine by 2050. The company’s long-term investments in genomics, AI in drug development, and sophisticated therapeutics should pay off. Biocon’s dedication to healthcare innovation and accessibility may make it a worldwide health leader. The pricing objective for 2050 is ₹3000. Our study predicts a price range of ₹2200 to ₹3000.
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2050 | 2200 | 3000 |
| Month | Minimum Price (₹) | Maximum Price (₹) |
| January | 2200 | 2250 |
| February | 2250 | 2300 |
| March | 2300 | 2350 |
| April | 2350 | 2400 |
| May | 2400 | 2450 |
| June | 2450 | 2500 |
| July | 2500 | 2600 |
| August | 2600 | 2700 |
| September | 2700 | 2800 |
| October | 2800 | 2850 |
| November | 2850 | 2900 |
| December | 2900 | 3000 |
Should I buy Biocon stock?
| Year | Minimum Price (₹) | Maximum Price (₹) |
| 2024 | 250 | 450 |
| 2025 | 300 | 530 |
| 2030 | 800 | 1000 |
| 2050 | 2200 | 3000 |
Many variables must be considered before investing in Biocon stock. Positive signs include the company’s biosimilar market position, research and development emphasis, and worldwide growth strategy. Investors should also consider biopharmaceutical sector competitiveness and regulatory issues.
Recent quarterly results show Biocon’s strong financial performance, with net income rising significantly. The company’s product expansion and market entry are remarkable. Biocon may appeal to biotechnology investors with a lower P/E ratio of 27.68.
Biocon Industries Ltd Earning Results
Biocon’s latest financial results show outstanding performance and development prospects. In the June 2024 quarter, Biocon reported consolidated sales of ₹34.33 billion, a small year-over-year rise. The net income increased significantly to ₹6.60 billion, suggesting increased profitability.
| Metric | Q1 FY2025 | Q1 FY2024 | YoY Change |
| Revenue | ₹34.33B | ₹34.23B | +0.30% |
| Net Income | ₹6.60B | ₹1.01B | +550.59% |
| EPS | ₹5.31 | ₹0.85 | +524.58% |
| EBITDA | ₹5.96B | ₹6.30B | -5.39% |
Expert Forecasts on the Future of Biocon Industries Ltd.
Industry analysts are enthusiastic about Biocon’s future. Analysts expect the company’s biosimilar and new biologic portfolio to fuel growth. Biocon’s worldwide growth, especially in developing countries, is welcomed.
Some analysts expect Biocon will gain from the increased need for inexpensive biopharmaceuticals, particularly in underdeveloped nations. They warn that regulatory clearances, price pressures, and rivalry from established pharmaceutical firms and biosimilar producers may affect the company’s business.
Is Biocon stock good to buy? (Bull case & Bear case)
Bull Case:
- Strength in biosimilar market growth
- New solid biologics and biosimilars pipeline
- Strategic ties with global drugmakers
- Entry into new markets, especially developing economies
- Focus on high-growth therapies like diabetes and cancer
Bear Case:
- Regulatory issues and product clearance delays
- Biopharmaceutical rivalry is fierce.
- Potential biosimilar pricing pressures
- R&D and clinical trial risks
- Currency fluctuations affect international operations
Conclusion
Biocon Industries Ltd. is a promising long-term biotechnology investment. The company’s excellent foundations, unique product pipeline, and strategic worldwide expansion equip it for growth. Our estimates suggest continuous price appreciation over the next several decades, but longer-term uncertainty increases.
Market variables may cause short-term volatility, but long-term investors may find Biocon appealing for portfolio growth. The company’s adaptability to market changes and investments in future technology may support continued success.
Before investing, you should study and assess your financial objectives and risk tolerance. The dynamic biopharmaceutical business requires diversification and portfolio evaluation to manage investment risks.
